To include your compound in the COVID-19 Resource Center, submit it here.

Celgene reports preliminary earnings, adds JAK inhibitor with Impact deal

Celgene Corp. (NASDAQ:CELG) reported preliminary 2017 results and 2018 guidance generally in line with expectations and said it will acquire Impact Biomedicines Inc. (San Diego, Calif.), gaining a late-stage hematology candidate in the process. The financial figures were presented at the JPMorgan Healthcare Conference in San Francisco.

The company reported 4Q17 sales of psoriasis drug Otezla

Read the full 550 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE